Phase 2 N=51 TRial on the Endocrine Activity of Neoadjuvant Degarelix
Breast Cancer Invasive Nos
Primary: Time to Optimal Ovarian Function Suppression — 14; 3 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=118 A Study LY2228820 for Recurrent Ovarian Cancer
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)
Phase 2 N=10 Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Maximum Decline From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) — -42095.14; -49065.88; -32947.50; -33149.13 Copies per milliliter
Phase 2 N=16 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
B-Cell Prolymphocytic Leukemia · Hypodiploidy · Loss of Chromosome 17p
Primary: Event-Free Survival (EFS) — 9 Participants
Phase 2 N=2,000 A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal.
Hepatitis
Primary: Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period — 0.0; 6.9; 0.3; 0.1 Percent of Participants
Phase 2 N=28 Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Complete Response, Assessed Using the International Myeloma Working Group (IMWG) Uniform Response Criteria — 0.48 proportion of patients
Phase 2 N=71 A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis
Atopic Dermatitis · Eczema
Primary: Number of Patients With Adverse Events — 7; 5; 1 Participants
Phase 2 N=69 A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis
Plaque Psoriasis
Primary: Patients Achieving a Physician's Global Assessment of "Clear" or "Almost Clear" at Any Time-point From Baseline to Day 42 of the Study — 4; 3 Participants
Phase 2 N=183 A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts
Common Warts
Primary: Complete Resolution of All Treated Warts by or at Week 12 — 2; 5; 2; 3 Participants
Phase 2 N=36 Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults
Malaria · Plasmodium Vivax
Primary: Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination…
Phase 2 N=75 Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Acquired Thrombotic Thrombocytopenic Purpura
Primary: Time-to-response of Treatment Defined by a Confirmed Recovery of Platelets ≥ 150,000/µL — 2.4; 4.3; 3; 4.9 days — p== 0.005
Phase 2 N=28 Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) — 28.6; 57.1 Percentage of participants
Phase 2 N=25 Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Stage IV Pancreatic Cancer
Primary: Complete Response Rate — 2; 15; 4; 3 Participants
Phase 2 N=23 Exercise and NutraStem (NT-020): Effects on Stem Cells
Adult Stem Cell Proliferation
Primary: Percentage of CD133+ Cells — 0.50; 0.28; 0.54; 0.47 percent of total
Phase 2 N=247 Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 — 30.7; 35.6; 42.5; 30.8 Percentage of participants — p=0.5224